Thyroid hormone therapy for older adults with subclinical hypothyroidism

dc.check.infoAccess to this article is restricted until 6 months after publication by the request of the publisher.en
dc.contributor.authorStott, David J.
dc.contributor.authorRodondi, Nicolas
dc.contributor.authorKearney, Patricia M.
dc.contributor.authorFord, Ian
dc.contributor.authorWestendorp, Rudi G. J.
dc.contributor.authorMooijaart, Simon P.
dc.contributor.authorSattar, Naveed
dc.contributor.authorAubert, Carole E.
dc.contributor.authorAujesky, Drahomir
dc.contributor.authorBauer, Douglas C.
dc.contributor.authorBaumgartner, Christine
dc.contributor.authorBlum, Manuel R.
dc.contributor.authorBrowne, John P.
dc.contributor.authorByrne, Stephen
dc.contributor.authorCollet, Tinh-Hai
dc.contributor.authorDekkers, Olaf M.
dc.contributor.authorden Elzen, Wendy P. J.
dc.contributor.authorDu Puy, Robert S.
dc.contributor.authorEllis, Graham
dc.contributor.authorFeller, Martin
dc.contributor.authorFloriani, Carmen
dc.contributor.authorHendry, Kirsty
dc.contributor.authorHurley, Caroline
dc.contributor.authorJukema, J. Wouter
dc.contributor.authorKean, Sharon
dc.contributor.authorKelly, Maria
dc.contributor.authorKrebs, Danielle
dc.contributor.authorLanghorne, Peter
dc.contributor.authorMcCarthy, Gemma
dc.contributor.authorMcCarthy, Vera J. C.
dc.contributor.authorMcConnachie, Alex
dc.contributor.authorMcDade, Mairi
dc.contributor.authorMessow, Martina
dc.contributor.authorO'Flynn, Anne Marie
dc.contributor.authorO'Riordan, David
dc.contributor.authorPoortvliet, Rosalinde K.E.
dc.contributor.authorQuinn, Terence J
dc.contributor.authorRussell, Audrey
dc.contributor.authorSinnott, Carol
dc.contributor.authorSmit, Jan W.A.
dc.contributor.authorVan Dorland, H. Anette
dc.contributor.authorWalsh, Kieran A.
dc.contributor.authorWalsh, Elaine K.
dc.contributor.authorWatt, Torquil
dc.contributor.authorWilson, Robbie
dc.contributor.authorGussekloo, Jacobijn
dc.contributor.funderSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschungen
dc.contributor.funderEuropean Commissionen
dc.contributor.funderSeventh Framework Programmeen
dc.contributor.funderSchweizerische Herzstiftungen
dc.contributor.funderVelux Stiftungen
dc.description.abstractBACKGROUND: The use of levothyroxine to treat subclinical hypothyroidism is controversial. We aimed to determine whether levothyroxine provided clinical benefits in older persons with this condition. Full Text of Background... METHODS: We conducted a double-blind, randomized, placebo-controlled, parallel-group trial involving 737 adults who were at least 65 years of age and who had persisting subclinical hypothyroidism (thyrotropin level, 4.60 to 19.99 mIU per liter; free thyroxine level within the reference range). A total of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 μg daily, or 25 μg if the body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according to the thyrotropin level; 369 patients were assigned to receive placebo with mock dose adjustment. The two primary outcomes were the change in the Hypothyroid Symptoms score and Tiredness score on a thyroid-related quality-of-life questionnaire at 1 year (range of each scale is 0 to 100, with higher scores indicating more symptoms or tiredness, respectively; minimum clinically important difference, 9 points). Full Text of Methods... RESULTS: The mean age of the patients was 74.4 years, and 396 patients (53.7%) were women. The mean (±SD) thyrotropin level was 6.40±2.01 mIU per liter at baseline; at 1 year, this level had decreased to 5.48 mIU per liter in the placebo group, as compared with 3.63 mIU per liter in the levothyroxine group (P<0.001), at a median dose of 50 μg. We found no differences in the mean change at 1 year in the Hypothyroid Symptoms score (0.2±15.3 in the placebo group and 0.2±14.4 in the levothyroxine group; between-group difference, 0.0; 95% confidence interval [CI], −2.0 to 2.1) or the Tiredness score (3.2±17.7 and 3.8±18.4, respectively; between-group difference, 0.4; 95% CI, −2.1 to 2.9). No beneficial effects of levothyroxine were seen on secondary-outcome measures. There was no significant excess of serious adverse events prespecified as being of special interest. Full Text of Results... CONCLUSIONS: Levothyroxine provided no apparent benefits in older persons with subclinical hypothyroidism.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.identifier.citationStott, D. J. et al. (2017) 'Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism', New England Journal of Medicine, 376(26), pp. 2534-2544. doi:10.1056/NEJMoa1603825en
dc.identifier.journaltitleNew England Journal of Medicineen
dc.publisherMassachusetts Medical Societyen
dc.relation.projectinfo:eu-repo/grantAgreement/EC/FP7::SP1::HEALTH/278148/EU/Multi-modal effects of thyroid hormone replacement for untreated older adults with subclinical hypothyroidism; a randomised placebo-controlled trial/TRUSTen
dc.rightsFrom New England Journal of Medicine, Stott et al, Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism, Copyright © 2017 Massachusetts Medical Society. Reprinted with permissionen
dc.subjectSubclinical hypothyroidismen
dc.subjectClinical trialen
dc.titleThyroid hormone therapy for older adults with subclinical hypothyroidismen
dc.typeArticle (peer-reviewed)en
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
518.4 KB
Adobe Portable Document Format
Published Version
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
2.71 KB
Item-specific license agreed upon to submission